ENTITY

Jiangsu Hengrui Pharmaceuticals (1276 HK)

316
Analysis
Health Care • China
Jiangsu Hengrui Pharmaceuticals is a global biopharmaceutical company engaged in the research, development, manufacturing, and commercialization of innovative and high-quality drugs. The company focuses on therapeutic areas including oncology, metabolic and cardiovascular diseases, immunological and respiratory diseases, and neuroscience. It was founded in 1970 and is headquartered in Lianyungang, Jiangsu, China.
more
•21 Jun 2026 10:15

A-H Premium Weekly (Jun 19th): China Longyuan, China Coal, Remegen, Yangtze Optical Fibre And-H

We analyzed A-H premium changes in the past week and highlight A-H premium changes for China Longyuan, China Coal, Remegen, Yangtze Optical Fibre...

Logo
121 Views
Share
bullish•SG Micro
•17 Jun 2026 15:07

SG Micro H Share Listing (3661 HK): Valuation Insights

SG Micro, a leading analog IC company in China, has launched an H Share listing to raise US$587 million. In this note, I discuss the H Share...

Logo
187 Views
Share
bullish•Lingyi iTech
•17 Jun 2026 14:40

Lingyi ITech H Share Listing (1688 HK): Valuation Insights

Lingyi iTech, a leading intelligent manufacturing platform for electronic devices, has launched an H Share listing to raise US$1.1 billion. In this...

Logo
181 Views
Share
•14 Jun 2026 10:15

A-H Premium Weekly (Jun 12th): Remegen, ZTE, Chalco, Shandong Gold Mining Co Lt-H

We analyzed A-H premium changes in the past week and highlight A-H premium changes for Remegen, ZTE, Chalco, Shandong Gold Mining Co Lt-H.

Logo
101 Views
Share
•07 Jun 2026 10:00

A-H Premium Weekly (Jun 5th): Yankuang Energy, Haier Smarthome, Times Electric, China Coal, Ping An

We analyzed A-H premium changes in the past week and highlight A-H premium changes for Yankuang Energy, Haier Smarthome, Times Electric, China...

Logo
138 Views
Share
x